Mercer Global Advisors Inc. ADV Has $2.04 Million Stock Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Mercer Global Advisors Inc. ADV grew its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 4.3% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 4,295 shares of the company’s stock after purchasing an additional 176 shares during the quarter. Mercer Global Advisors Inc. ADV’s holdings in IDEXX Laboratories were worth $2,039,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Vanguard Group Inc. raised its stake in IDEXX Laboratories by 1.2% during the first quarter. Vanguard Group Inc. now owns 8,476,054 shares of the company’s stock worth $4,576,476,000 after buying an additional 98,387 shares during the last quarter. Capital World Investors raised its position in shares of IDEXX Laboratories by 1.1% in the 4th quarter. Capital World Investors now owns 1,022,678 shares of the company’s stock worth $567,648,000 after acquiring an additional 11,351 shares in the last quarter. American Century Companies Inc. lifted its stake in shares of IDEXX Laboratories by 46.0% in the 2nd quarter. American Century Companies Inc. now owns 562,764 shares of the company’s stock valued at $274,179,000 after purchasing an additional 177,226 shares during the period. Dimensional Fund Advisors LP boosted its position in shares of IDEXX Laboratories by 13.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 512,788 shares of the company’s stock valued at $249,855,000 after purchasing an additional 59,519 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA grew its stake in IDEXX Laboratories by 12.5% during the second quarter. Massachusetts Financial Services Co. MA now owns 390,565 shares of the company’s stock worth $190,283,000 after purchasing an additional 43,473 shares during the period. Institutional investors and hedge funds own 87.84% of the company’s stock.

IDEXX Laboratories Stock Up 0.2 %

Shares of NASDAQ IDXX opened at $507.66 on Tuesday. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.37 and a quick ratio of 1.03. IDEXX Laboratories, Inc. has a 1 year low of $372.50 and a 1 year high of $583.39. The stock has a market capitalization of $41.93 billion, a P/E ratio of 49.14, a P/E/G ratio of 4.17 and a beta of 1.33. The company has a 50-day moving average price of $484.35 and a 200-day moving average price of $498.35.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Tuesday, August 6th. The company reported $2.44 EPS for the quarter, missing analysts’ consensus estimates of $2.88 by ($0.44). IDEXX Laboratories had a return on equity of 57.03% and a net margin of 22.34%. The company had revenue of $1 billion for the quarter, compared to the consensus estimate of $1.01 billion. During the same period in the prior year, the firm posted $2.67 earnings per share. The business’s revenue for the quarter was up 6.4% on a year-over-year basis. On average, equities research analysts forecast that IDEXX Laboratories, Inc. will post 10.45 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have issued reports on IDXX. Stifel Nicolaus dropped their price target on IDEXX Laboratories from $520.00 to $510.00 and set a “hold” rating on the stock in a research note on Monday, June 24th. StockNews.com cut shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday, July 10th. Piper Sandler dropped their price objective on shares of IDEXX Laboratories from $600.00 to $520.00 and set a “neutral” rating on the stock in a report on Wednesday, August 14th. Finally, BTIG Research initiated coverage on shares of IDEXX Laboratories in a research report on Thursday, July 25th. They set a “buy” rating and a $580.00 price objective on the stock. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, IDEXX Laboratories has an average rating of “Moderate Buy” and an average price target of $582.25.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.